Genmab (GMAB) said Monday that Johnson & Johnson (JNJ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38.
Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab has decided not to proceed with further development after evaluating the data, market landscape, and portfolio priorities, the biotechnology company said.
Under the development and option agreement between the companies for HexaBody-CD38, Genmab supplied Johnson & Johnson with data from a clinical proof-of-concept study in multiple myeloma, which included a head-to-head comparison with Darzalex Faspro, the company said.
Shares of Genmab were down more than 7% in recent Monday trading.
Price: 22.23, Change: -1.92, Percent Change: -7.93
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。